drug

LYN-005

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Lyndra Inc.
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
NCT05779241Phase 3Completed
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
NCT04567524Phase 2Completed

KOLs & investigators

1
Richard Scranton, MD, MPHKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Lyndra Inc.
company
trial
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
PHASE3
trial
A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules
PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia Schizoaffective
indication
Schizophrenia
indication
Psychotic Disorders
indication
KOL
Richard Scranton, MD, MPH
KOL score 5
person